Multi-target approach for natural products in inflammation
Andreas Koeberle1, Oliver Werz1
1Institute of Pharmacy, Friedrich-Schiller-University, Philosophenweg 14, 07743 Jena, Germany.
Drug Discovery Today
|August 31, 2014
Summary
Natural products offer potential for multi-target drug discovery, particularly for inflammation. This review explores strategies for using compounds like curcumin to develop effective anti-inflammatory drugs by targeting multiple pathways.
Area of Science:
- Pharmacology
- Natural Products Chemistry
- Drug Discovery
Background:
- Multi-target natural products show preclinical efficacy and safety but are underutilized in drug discovery.
- Natural products possess privileged structures with vast pharmacological knowledge.
- Developing multi-target drugs is crucial for complex diseases like inflammation.
Purpose of the Study:
- To provide an overview of the multi-target drug concept.
- To discuss strategies for utilizing natural products in multi-target drug discovery for inflammation.
- To focus on target selection, relevance assessment, and safety considerations.
Main Methods:
- Literature review on multi-target drug discovery and natural products.
- Analysis of privileged natural product structures (curcumin, epigallocatechin-3-gallate, resveratrol, salicylate, quercetin).
- Discussion of strategies for modulating natural product affinity to specific molecular targets.
Main Results:
- Natural products offer a rich source for multi-target anti-inflammatory drug development.
- Key natural products like curcumin and resveratrol have broad target profiles relevant to inflammation.
- Strategies exist to refine natural product activity towards specific inflammation-related pathways.
Conclusions:
- Natural products with privileged structures are valuable starting points for multi-target anti-inflammatory drug discovery.
- Careful selection of molecular targets and safety assessment are essential.
- Modulating natural product affinity can optimize efficacy while retaining beneficial broad activity.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
867
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867
01:26Targets for Drug Action: Overview
9.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.0K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:38Inflammation
46.1K
Overview
46.1K
01:27Combined Effects of Drugs: Synergism
6.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.0K
01:26Acute Inflammation I: Inflammatory Response
64
Acute inflammation is a rapid, short-lived physiological response to tissue injury or infection, designed to eliminate harmful agents and initiate repair. This tightly regulated process typically lasts from minutes to several days and is triggered by factors such as microbial invasion, physical trauma, or chemical injury.Recognition and Mediator ReleaseThe inflammatory response begins when resident immune cells—such as mast cells, macrophages, and dendritic cells—detect...
64